FOI release

Reclassification of Pepcid AC/famotidine from POM to P and P to GSL

This request was refused in part, so we didn't provide some of the information the requester asked for. This may include information where we can neither confirm nor deny that we hold it.

Case reference FOI2026/00114

Received 3 February 2026

Published 6 May 2026

Request

We would like to request copies of the below documents related to the reclassifications of famotidine 10mg / Pepcid AC (Famotidine 10mg; PL 00025/0312 (Merck, Sharp & Dohme Limited, Hoddesdon, UK)  from;        a)    a POM to P medicine (1994)       and from;       b)    a P to GSL medicine (2000) Requested documents:       1)    Copies of the reclassification submission documents (redacted if necessary)       2)    Copies of the assessors’ report (redacted if necessary)       3)    Associated Annexes to the report       4)    Stakeholder comments to the reclassification (or summary of these if appropriate)                 5) Copies of any educational materials approved with either of these switch applications  

Response

See attached

Documents

• FOI2026_00114 (redacted).pdf (1.1 MB)
• POM-P and P-GSL Reclassification (redacted) to be released.pdf (93.4 MB)

This is Medicines and Healthcare products Regulatory Agency's response to a freedom of information (FOI) or environmental information regulations (EIR) request.

You can browse our other responses or make a new FOI request.